S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.17
0.00 (0.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.17
▼
$0.19
50-Day Range
$0.11
▼
$0.19
52-Week Range
$0.10
▼
$0.62
Volume
1.95 million shs
Average Volume
1.51 million shs
Market Capitalization
$21.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.00mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

See Top Rated MarketRank™ Stocks Here
CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

February 5, 2023 | americanbankingnews.com
Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by Analysts at StockNews.com
January 31, 2023 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, outperforms market
February 5, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
January 28, 2023 | americanbankingnews.com
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives New Coverage from Analysts at StockNews.com
January 24, 2023 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock remains steady Tuesday, still outperforms market
December 15, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, outperforms market
December 14, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock falls Wednesday, underperforms market
November 10, 2022 | finance.yahoo.com
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
November 8, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 25, 2022 | msn.com
Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket
October 14, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
September 26, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
September 22, 2022 | finance.yahoo.com
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
September 12, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
August 9, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 6, 2022 | finance.yahoo.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
May 10, 2022 | apnews.com
Corbus Pharmaceuticals: Q1 Earnings Snapshot
May 10, 2022 | seekingalpha.com
Corbus Pharmaceuticals GAAP EPS of -$0.08 beats by $0.01
May 10, 2022 | markets.businessinsider.com
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 18, 2022 | msn.com
Marijuana Stock Movers For April 18, 2022
April 8, 2022 | finance.yahoo.com
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
April 7, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors
April 7, 2022 | msn.com
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
April 5, 2022 | msn.com
Cannabis Stock Gainers And Losers From April 5, 2022
April 4, 2022 | marketwatch.com
Corbus Pharmaceuticals Holdings Inc. stock falls Monday, underperforms market
March 11, 2022 | finance.yahoo.com
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/08/2022
Today
2/05/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
CUSIP
N/A
CIK
1595097
Web
www.corbuspharma.com
Phone
(617) 963-0100
Fax
617-663-6085
Employees
41
Year Founded
2009

Profitability

EPS (Most Recent Fiscal Year)
($0.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-45,640,000.00
Net Margins
N/A
Pretax Margin
-36,209.27%
Return on Equity
-66.27%
Return on Assets
-40.89%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
3.86
Quick Ratio
3.86

Sales & Book Value

Annual Sales
$880,000.00
Price / Sales
24.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.55 per share
Price / Book
0.31

Miscellaneous

Outstanding Shares
125,280,000
Free Float
115,008,000
Market Cap
$21.49 million
Optionable
Optionable
Beta
2.14

Social Links


Key Executives

  • Yuval CohenYuval Cohen
    Chief Executive Officer & Director
  • Craig Millian
    Chief Operating Officer
  • Sean F. Moran
    Chief Financial & Accounting Officer
  • Rachael Brake
    Chief Scientific Officer
  • Brian Walsh
    Vice President-Corporate Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CRBP Stock - Frequently Asked Questions

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of the year. Since then, CRBP stock has increased by 55.2% and is now trading at $0.1715.
View the best growth stocks for 2023 here.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CRBP earnings forecast.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.17.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $21.49 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 2/5/2023 by MarketBeat.com Staff